Inhibrx shares surge after bone cancer drug slows disease progression in trial [Yahoo! Finance Canada]
Inhibrx, Inc. (INBX)
Company Research
Source: Yahoo! Finance Canada
In the 206-patient study, the drug, ozekibart, extended the time patients lived without their cancer worsening to 5.52 months, compared with 2.66 months for those on placebo. Inhibrx said it plans to submit a marketing application to the U.S. Food and Drug Administration in the second quarter of 2026. The company was testing the drug to treat chondrosarcoma, a rare type of cancer that starts in the bones and mainly affects the cartilage, the flexible tissue around joints. There are currently no FDA-approved treatments for the disease. The drug also helped control the disease and improved patients' quality of life, including delaying pain and physical decline. The benefit was seen across different patient groups, including those with and without IDH mutations, which are common in chondrosarcoma. "I am very encouraged and enthusiastic about ozekibart and the impact I have seen on my sarcoma patients," said Dr Robin Jones of the Royal Marsden Hospital in London. The treatmen
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- Best Quant-rated small- and mid-cap healthcare stocks as LLY hits $1T in market cap [Seeking Alpha]Seeking Alpha
- Inhibrx Biosciences (NASDAQ:INBX) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Inhibrx Biosciences GAAP EPS of -$2.28 [Seeking Alpha]Seeking Alpha
- Inhibrx Reports Third Quarter 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Inhibrx Reports Third Quarter 2025 Financial ResultsPR Newswire
INBX
Earnings
- 8/13/25 - Beat
INBX
Analyst Actions
- 11/19/25 - Citigroup Inc.
INBX
Sec Filings
- 11/14/25 - Form 10-Q
- 11/14/25 - Form 8-K
- 10/23/25 - Form 8-K
- INBX's page on the SEC website